Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders

The following table sets forth the computation of the basic and diluted net loss per share attributable to Guardant Health, Inc. common stockholders:



	Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018

	(unaudited)
	(in thousands, except per share data)
Net loss	$	(11,300	)	$	(21,639	)	$	(32,651	)	$	(35,483	)
Fair value adjustment of redeemable noncontrolling interest	(300		)	—			(5,000		)	—
Net loss attributable to Guardant Health, Inc. common stockholders, basic and diluted	$	(11,600	)	$	(21,639	)	$	(37,651	)	$	(35,483	)
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted	$	(0.13	)	$	(1.75	)	$	(0.43	)	$	(2.92	)
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted	89,036			12,388			87,494			12,155

Since the Company was in a loss position for all periods presented, basic net loss per share attributable to Guardant Health, Inc. common stockholders is the same as diluted net loss per share attributable to Guardant Health, Inc. common stockholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Guardant Health, Inc. common stockholders for the periods presented as they had an anti-dilutive effect:



	Three Months Ended June 30,		Six Months Ended June 30,
	2019	2018	2019	2018

	(unaudited)
	(in thousands)
Convertible preferred stock (on an as if converted basis)	—	58,265	—	58,265
Stock options issued and outstanding	6,313	7,247	6,908	7,352
Unvested restricted stock units	122	—	100	—
ESPP obligation	83	—	71	—
Preferred stock warrants (on an as if converted basis)	—	8	—	8
Common stock warrants	—	279	—	296
Common stock subject to repurchase	32	58	37	38
Total	6,550	65,857	7,116	65,959